VEGFA and colorectal carcinoma: CAFs extracted from tissue samples of cisplatin-resistant CRC patients deliver VEGFA to HT29 cells via exosomes, thus promoting cells resistance to cisplatin, enhancing cell viability, reducing cell apoptosis, and promoting angiogenesis143.